Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study

Hepatology

Volumn 61, Issue 4, 2015, Pages 1205-1215

  Oh, Sechang ^a   Shida, Takashi ^b   Yamagishi, Kazumasa ^a   Tanaka, Kiyoji ^b   So, Rina ^b   Tsujimoto, Takehiko ^b   Shoda, Junichi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ACYL COENZYME A OXIDASE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID SYNTHASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ACCELEROMETER; ADULT; AEROBIC EXERCISE; APOPTOSIS; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; DIET RESTRICTION; DIETARY INTAKE; DISEASE SEVERITY; ENERGY EXPENDITURE; EXERCISE INTENSITY; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; FERRITIN BLOOD LEVEL; GENE EXPRESSION; HEALTH PROGRAM; HUMAN; HUMAN CELL; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID COMPOSITION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; METABOLIC EQUIVALENT; MIDDLE AGED; MODERATE TO VIGOROUS PHYSICAL ACTIVITY; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WEIGHT REDUCTION; COMPLICATION; EVALUATION STUDY; KINESIOTHERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES;

EXERCISE THERAPY; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RETROSPECTIVE STUDIES;

EID: 84925362378     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27544     Document Type: Article

References (36)

1. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47:586-595.
2. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006;6:19-25.
3. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007;56:1760-1769.
4. Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol 2011;111:1828-1835.
5. Bae JC, Suh S, Park SE, Rhee EJ, Park CY, Oh KW, et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One 2012;7:e46819.
6. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-1112.
7. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011;60:1278-1283.
8. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50:68-76.
9. Oh S, Tanaka K, Warabi E, Shoda J. Exercise reduces inflammation and oxidative stress in obesity-related liver diseases. Med Sci Sports Exerc 2013;45:2214-2222.
10. Oh S, Tanaka K, Tsujimoto T, So R, Shida T, Shoda J. Regular exercise coupled to diet regimen accelerates reduction of hepatic steatosis and associated pathological conditions in nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2014;12:290-298.
11. Finelli C, Tarantino G. Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol 2012;18:6790-6800.
12. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet 2005;94:1-12.
13. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775-777.
14. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
15. Kumahara H, Schutz Y, Ayabe M, Yoshioka M, Yoshitake Y, Shindo M, et al. The use of uniaxial accelerometry for the assessment of physical-activity-related energy expenditure: a validation study against whole-body indirect calorimetry. Br J Nutr 2004;91:235-243.
16. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-407.
17. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.
18. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled Attenuation Parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825-1835.
19. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
20. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854.
21. Bouwens M, Grootte Bromhaar M, Jansen J, Müller M, Afman LA. Postprandial dietary lipid-specific effects on human peripheral blood mononuclear cell gene expression profiles. Am J Clin Nutr 2010;91:208-217.
22. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867.
23. Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol 2006;40:930-935.
24. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008;87:1374-1383.
25. Lemasters JJ, Uchiyama A, Kim J-S, Kon K, Jaeschke H. Role of intracellular iron movement and oxidant stress in hepatocellular injury. In: Arias I, Wolkoff A, Boyer J, Shafritz D, Fausto N, Alter H, et al., editors. The liver: biology and pathobiology. Hoboken, NJ: John Wiley & Sons; 2009. p 511-520.
26. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011;106:460-468.
27. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-1846.
28. Kim SY, Lee YS. Effects of exercise on redox-sensitive transcription factor Nrf2-driven expression of HO-1 and NQO1 in human peripheral blood mononuclear cells. KAPHED 2010;49:419-430.
29. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 2013;53:401-426.
30. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 2009;620:138-144.
31. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008;14:185-192.
32. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013;19:802-812.
33. Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 2008;48:458-473.
34. Johnson NA, Keating SE, George J. Exercise and the liver: implications for therapy in fatty liver disorders. Semin Liver Dis 2012;32:65-79.
35. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for Prescribing Exercise. Med Sci Sports Exerc 2011;43:1334-1359.
36. Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009;41:459-471.